原发性肿瘤位置对转移性结直肠癌治疗的预测作用：一份加拿大共识声明。
The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement.
作者信息
Abrahao A B K, Karim S, Colwell B, Berry S, Biagi J
机构信息
Department of Oncology, Sunnybrook Health Sciences Centre, Toronto, ON.
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, ON.
出版信息
Curr Oncol. 2017 Dec;24(6):390-400. doi: 10.3747/co.24.3757. Epub 2017 Dec 20.
Abstract
In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts.
摘要
在最近公布的数据中，已对原发性肿瘤位置对于采用现有生物疗法治疗转移性结直肠癌的预测价值进行了探索。认识到这些数据对临床实践的潜在影响，我们召集了治疗转移性结直肠癌的加拿大专家会议，以制定一套基于原发性肿瘤位置的全国性、循证治疗指南。本报告总结了相关证据，并介绍了这些专家的共识性建议。
相似文献
1
The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement.
Curr Oncol. 2017 Dec;24(6):390-400. doi: 10.3747/co.24.3757. Epub 2017 Dec 20.
2
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
World J Gastroenterol. 2016 Aug 14;22(30):6944-54. doi: 10.3748/wjg.v22.i30.6944.
3
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19.
4
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.
5
Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.
Drugs. 2015 Oct;75(15):1739-56. doi: 10.1007/s40265-015-0459-x.
6
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.
7
TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Tumour Biol. 2015 Jun;36(6):4301-8. doi: 10.1007/s13277-015-3069-z. Epub 2015 Jan 23.
8
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Angiogenesis. 2014 Oct;17(4):805-21. doi: 10.1007/s10456-014-9433-6. Epub 2014 May 3.
9
Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
Br J Cancer. 2015 Aug 11;113(4):680-5. doi: 10.1038/bjc.2015.250. Epub 2015 Jul 14.
10
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Clin Colorectal Cancer. 2014 Sep;13(3):145-55. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 26.
引用本文的文献
1
Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with Wild-Type Left-Sided Tumours in Canada.
Curr Oncol. 2023 Sep 6;30(9):8220-8232. doi: 10.3390/curroncol30090596.
2
Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28-29, October 2022.
Curr Oncol. 2023 Aug 29;30(9):7964-7983. doi: 10.3390/curroncol30090579.
3
Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives.
J Clin Transl Res. 2021 Aug 4;7(4):511-522. eCollection 2021 Aug 26.
4
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Curr Oncol. 2021 Jan 15;28(1):523-548. doi: 10.3390/curroncol28010053.
5
Current and emerging biomarkers in metastatic colorectal cancer.
Curr Oncol. 2019 Nov;26(Suppl 1):S7-S15. doi: 10.3747/co.26.5719. Epub 2019 Nov 1.
6
Cost-effectiveness analysis of selective first-line use of biologics for unresectable wild-type left-sided metastatic colorectal cancer.
Curr Oncol. 2019 Oct;26(5):e597-e609. doi: 10.3747/co.26.4843. Epub 2019 Oct 1.
本文引用的文献
1
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119.
2
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Ann Oncol. 2017 Aug 1;28(8):1713-1729. doi: 10.1093/annonc/mdx175.
3
Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.
Future Oncol. 2017 May;13(12):1115-1127. doi: 10.2217/fon-2016-0468. Epub 2017 Jan 23.
4
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.
5
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.
JAMA Oncol. 2017 Feb 1;3(2):211-219. doi: 10.1001/jamaoncol.2016.4227.
6
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
JAMA Oncol. 2017 Feb 1;3(2):194-201. doi: 10.1001/jamaoncol.2016.3797.
7
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
J Clin Oncol. 2015 Nov 10;33(32):3718-26. doi: 10.1200/JCO.2015.61.2887. Epub 2015 Aug 10.
8
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.
9
Primary tumor location as a prognostic factor in metastatic colorectal cancer.
J Natl Cancer Inst. 2015 Feb 24;107(3). doi: 10.1093/jnci/dju427. Print 2015 Mar.
10
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
J Clin Oncol. 2015 Mar 1;33(7):692-700. doi: 10.1200/JCO.2014.59.4812. Epub 2015 Jan 20.
Zotero 插件